Study design and participant characteristics of a randomized controlled trial of directly administered antiretroviral therapy in opioid treatment programs

Bernadette Anna Mullen, Katie Cook, Richard D Moore, Cynthia Rand, Noya Galai, Mary E McCaul, Sheldon Glass, Krisann K Oursler, Gregory M Lucas, Bernadette Anna Mullen, Katie Cook, Richard D Moore, Cynthia Rand, Noya Galai, Mary E McCaul, Sheldon Glass, Krisann K Oursler, Gregory M Lucas

Abstract

Background: HIV-infected drug users are at higher risk of non-adherence and poor treatment outcomes than HIV-infected non-drug users. Prior work from our group and others suggests that directly administered antiretroviral therapy (DAART) delivered in opioid treatment programs (OTPs) may increase rates of viral suppression.

Methods/design: We are conducting a randomized trial comparing DAART to self-administered therapy (SAT) in 5 OTPs in Baltimore, Maryland. Participants and investigators are aware of treatment assignments. The DAART intervention is 12 months. The primary outcome is HIV RNA < 50 copies/mL at 3, 6, and 12 months. To assess persistence of any study arm differences that emerge during the active intervention, we are conducting an 18-month visit (6 months after the intervention concludes). We are collecting electronic adherence data for 2 months in both study arms. Of 457 individuals screened, a total of 107 participants were enrolled, with 56 and 51 randomly assigned to DAART and SAT, respectively. Participants were predominantly African American, approximately half were women, and the median age was 47 years. Active use of cocaine and other drugs was common at baseline. HIV disease stage was advanced in most participants. The median CD4 count at enrollment was 207 cells/mm3, 66 (62%) had a history of an AIDS-defining opportunistic condition, and 21 (20%) were antiretroviral naïve.

Conclusions: This paper describes the rationale, methods, and baseline characteristics of subjects enrolled in a randomized clinical trial comparing DAART to SAT in opioid treatment programs.

Trial registration: ClinicalTrials.gov: NCT00279110.

Figures

Figure 1
Figure 1
Disposition of individuals screened for a trial comparing directly administered antiretroviral therapy to self-administered therapy in opioid treatment programs, Baltimore, Maryland. ART, antiretroviral therapy; DHHS, Department of Health and Human Services; DAART, directly administered antiretroviral therapy; SAT, self-administered therapy.

References

    1. Chaulk CP, Kazandjian VA. Directly observed therapy for treatment completion of pulmonary tuberculosis: Consensus Statement of the Public Health Tuberculosis Guidelines Panel [published erratum appears in JAMA 1998 Jul 8;280(2):134] JAMA. 1998;279:943–948. doi: 10.1001/jama.279.12.943.
    1. Ford N, Nachega JB, Engel ME, Mills EJ. Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomised clinical trials. Lancet. 2009;374:2064–2071. doi: 10.1016/S0140-6736(09)61671-8.
    1. Hart JE, Jeon CY, Ivers LC, Behforouz HL, Caldas A, Drobac PC. et al.Effect of directly observed therapy for highly active antiretroviral therapy on virologic, immunologic, and adherence outcomes: a meta-analysis and systematic review. J Acquir Immune Defic Syndr. 2010;54:167–179.
    1. Goggin K, Liston RJ, Mitty JA. Modified directly observed therapy for antiretroviral therapy: a primer from the field. Public Health Rep. 2007;122:472–481.
    1. Berg KM, Mouriz J, Li X, Duggan E, Goldberg U, Arnsten JH. Rationale, design, and sample characteristics of a randomized controlled trial of directly observed antiretroviral therapy delivered in methadone clinics. Contemp Clin Trials. 2009;30:481–489. doi: 10.1016/j.cct.2009.05.003.
    1. Berg KM, Litwin A, Li X, Heo M, Arnsten JH. Directly observed antiretroviral therapy improves adherence and viral load in drug users attending methadone maintenance clinics: A randomized controlled trial. Drug Alcohol Depend. 2010.
    1. Lucas GM, Mullen BA, Weidle PJ, Hader S, McCaul ME, Moore RD. Directly Administered Antiretroviral Therapy in Methadone Clinics Is Associated with Improved HIV Treatment Outcomes, Compared with Outcomes among Concurrent Comparison Groups. Clin Infect Dis. 2006;42:1628–1635. doi: 10.1086/503905.
    1. Panel on Clinical Practices for the Treatment of HIV Infection: Department of Health and Human Services. Guidelines for the Use of Antiretroviral Therapy in HIV-1-Infected Adults and Adolescents: March 23, 2004. [last accessed January 2011]
    1. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D. et al.Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med. 2009;17:138–145.
    1. Andresen EM, Malmgren JA, Carter WB, Patrick DL. Screening for depression in well older adults: evaluation of a short form of the CES-D (Center for Epidemiologic Studies Depression Scale) Am J Prev Med. 1994;10:77–84.
    1. Derogatis LR, Melisaratos N. The Brief Symptom Inventory: an introductory report. Psychol Med. 1983;13:595–605. doi: 10.1017/S0033291700048017.
    1. Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr. 2001;27:251–259.
    1. Saunders JB, Aasland OG, Babor TF, de lF Jr, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II. Addiction. 1993;88:791–804. doi: 10.1111/j.1360-0443.1993.tb02093.x.
    1. Conway B, Prasad J, Reynolds R, Farley J, Jones M, Jutha S. et al.Directly observed therapy for the management of HIV-infected patients in a methadone program. Clin Infect Dis. 2004;38(Suppl 5):S402–8. doi: 10.1086/421404. S402-S408.
    1. Altice FL, Friedland GH, Cooney EL. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS. 1999;13:957–962. doi: 10.1097/00002030-199905280-00012.
    1. Gourevitch MN, Friedland GH. Interactions between methadone and medications used to treat HIV infection: A review [In Process Citation] Mt Sinai J Med. 2000;67:429–436.
    1. Centers for Disease Control and Prevention. 1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults. MMWR. 1992;41(RR-17):1–19.
    1. Lucas GM, Mullen BA, McCaul ME, Weidle PJ, Hader S, Moore RD. Adherence, drug use, and treatment failure in a methadone-clinic-based program of directly administered antiretroviral therapy. AIDS Patient Care STDS. 2007;21:564–574. doi: 10.1089/apc.2006.0192.
    1. Arnsten JH, Demas PA, Grant RW, Gourevitch MN, Farzadegan H, Howard AA. et al.Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17:377–381.
    1. Lucas GM, Griswold M, Gebo KA, Keruly J, Chaisson RE, Moore RD. Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy. Am J Epidemiol. 2006;163:412–420. doi: 10.1093/aje/kwj059.
    1. Wohl AR, Garland WH, Valencia R, Squires K, Witt MD, Kovacs A. et al.A Randomized Trial of Directly Administered Antiretroviral Therapy and Adherence Case Management Intervention. Clin Infect Dis. 2006;42:1619–1627. doi: 10.1086/503906.
    1. Macalino GE, Hogan JW, Mitty JA, Bazerman LB, Delong AK, Loewenthal H. et al.A randomized clinical trial of community-based directly observed therapy as an adherence intervention for HAART among substance users. AIDS. 2007;21:1473–1477. doi: 10.1097/QAD.0b013e32811ebf68.
    1. Altice FL, Maru DS, Bruce RD, Springer SA, Friedland GH. Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial. Clin Infect Dis. 2007;45:770–778. doi: 10.1086/521166.
    1. Gross R, Tierney C, Andrade A, Lalama C, Rosenkranz S, Eshleman SH. et al.Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naive HIV-1-infected patients: a randomized trial. Arch Intern Med. 2009;169:1224–1232. doi: 10.1001/archinternmed.2009.172.
    1. Nachega JB, Chaisson RE, Goliath R, Efron A, Chaudhary MA, Ram M. et al.Randomized controlled trial of trained patient-nominated treatment supporters providing partial directly observed antiretroviral therapy. AIDS. 2010;24:1273–1280.
    1. Pearson CR, Micek MA, Simoni JM, Hoff PD, Matediana E, Martin DP. et al.Randomized control trial of peer-delivered, modified directly observed therapy for HAART in Mozambique. J Acquir Immune Defic Syndr. 2007;46:238–244. doi: 10.1097/QAI.0b013e318153f7ba.
    1. Sarna A, Luchters S, Geibel S, Chersich MF, Munyao P, Kaai S, Short- and Long-Term Efficacy of Modified Directly Observed Antiretroviral Treatment in Mombasa, Kenya: A Randomized Trial. J Acquir Immune Defic Syndr. 2008.
    1. Taiwo BO, Idoko JA, Welty LJ, Otoh I, Job G, Iyaji PG. et al.Assessing the Viorologic and Adherence Benefits of Patient-Selected HIV Treatment Partners in a Resource-limited Setting. J Acquir Immune Defic Syndr. 2010;54:85–92. doi: 10.1097/01.qai.0000371678.25873.1c.
    1. Flanigan TP, Mitty JA. The Good, the Bad, and the Ugly: Providing Highly Active Antiretroviral Therapy When It Is Most Difficult. Clin Infect Dis. 2006;42:1636–1638. doi: 10.1086/503916.
    1. Bangsberg DR, Mundy LM, Tulsky JP. Expanding directly observed therapy: tuberculosis to human immunodeficiency virus. Am J Med. 2001;110:664–666. doi: 10.1016/S0002-9343(01)00729-X.
    1. Goldie SJ, Paltiel AD, Weinstein MC, Losina E, Seage GR III, Kimmel AD. et al.Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med. 2003;115:632–641. doi: 10.1016/j.amjmed.2003.07.007.
    1. Maru DS, Bruce RD, Walton M, Springer SA, Altice FL. Persistence of virological benefits following directly administered antiretroviral therapy among drug users: results from a randomized controlled trial. J Acquir Immune Defic Syndr. 2009;50:176–181. doi: 10.1097/QAI.0b013e3181938e7e.
    1. Taiwo BO, Idoko JA, Marcelin AG, Otoh I, Reddy S, Iyaji PG. et al.Patient-selected treatment partners did not protect against drug resistance during first-line NNRTI-based HAART in a randomized trial. J Acquir Immune Defic Syndr. 2010;54:563–565. doi: 10.1097/QAI.0b013e3181e5112f.
    1. Brust JC, Litwin AH, Berg KM, Li X, Heo M, Arnsten JH. Directly Observed Antiretroviral Therapy in Substance Abusers Receiving Methadone Maintenance Therapy Does Not Cause Increased Drug Resistance. AIDS Res Hum Retroviruses. 2010.
    1. Maru DS, Kozal MJ, Bruce RD, Springer SA, Altice FL. Directly administered antiretroviral therapy for HIV-infected drug users does not have an impact on antiretroviral resistance: results from a randomized controlled trial. J Acquir Immune Defic Syndr. 2007;46:555–563. doi: 10.1097/QAI.0b013e318158c0bd.
    1. Wohl DA, Stephenson BL, Golin CE, Kiziah CN, Rosen D, Ngo B. et al.Adherence to directly observed antiretroviral therapy among human immunodeficiency virus-infected prison inmates. Clin Infect Dis. 2003;36:1572–1576. doi: 10.1086/375076.
    1. Celentano DD, Galai N, Sethi AK, Shah NG, Strathdee SA, Vlahov D. et al.Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS. 2001;15:1707–1715. doi: 10.1097/00002030-200109070-00015.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner